EP 1149113 A1 20011031 - USE OF AGONISTS OR ANTAGONISTS OF MIP-3A IN THERAPY
Title (en)
USE OF AGONISTS OR ANTAGONISTS OF MIP-3A IN THERAPY
Title (de)
VERWENDUNG VON AGONISTEN ODER ANTAGONISTEN VON MIP-3A IN DER THERAPIE
Title (fr)
UTILISATION D'AGONISTES OU D'ANTAGONISTES DE LA CHIMIOKINE MIP-3A A DES FINS THERAPEUTIQUES
Publication
Application
Priority
- US 0000511 W 20000202
- US 24428199 A 19990203
Abstract (en)
[origin: WO0046248A1] Agonists or antagonists of MIP-3 alpha , and various methods of use in dermatological and related applications are provided. In particular, the method makes use of fact that the MIP-3 alpha chemokine is specifically capable of inducing migration of a skin cell subset.
IPC 1-7
C07K 14/52; C07K 14/715; C07K 16/24; C07K 16/28; C12N 5/06; A61P 17/00; A61P 35/00; A61P 37/06
IPC 8 full level
A61K 38/00 (2006.01); A61K 38/19 (2006.01); A61K 38/22 (2006.01); A61K 39/39 (2006.01); A61K 39/395 (2006.01); A61K 45/00 (2006.01); A61K 45/06 (2006.01); A61P 9/08 (2006.01); A61P 17/00 (2006.01); A61P 25/04 (2006.01); A61P 29/00 (2006.01); A61P 31/04 (2006.01); A61P 31/10 (2006.01); A61P 31/12 (2006.01); A61P 35/00 (2006.01); A61P 35/04 (2006.01); A61P 37/02 (2006.01); A61P 37/06 (2006.01)
CPC (source: EP)
A61K 38/195 (2013.01); A61K 45/06 (2013.01); A61P 9/08 (2017.12); A61P 17/00 (2017.12); A61P 25/04 (2017.12); A61P 29/00 (2017.12); A61P 31/04 (2017.12); A61P 31/10 (2017.12); A61P 31/12 (2017.12); A61P 35/00 (2017.12); A61P 35/04 (2017.12); A61P 37/02 (2017.12); A61P 37/06 (2017.12)
Citation (search report)
See references of WO 0046248A1
Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
DOCDB simple family (publication)
WO 0046248 A1 20000810; AU 2962200 A 20000825; CA 2362091 A1 20000810; EP 1149113 A1 20011031; JP 2002540068 A 20021126
DOCDB simple family (application)
US 0000511 W 20000202; AU 2962200 A 20000202; CA 2362091 A 20000202; EP 00908238 A 20000202; JP 2000597318 A 20000202